Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Active Treatment- CT1812 · 1 trial · 1 indication
Number of subjects reported with AEs and the number of AEs reported following administration of the IP summarized by treatment and grouped according to system organ class and preferred term, using descriptive statistics. Summaries of AEs were also presented by severity and by relationship to investigational product. In these summaries, subjects were counted only once per MedDRA term, for the AE of highest severity or least favorable relationship. Summaries were also presented of SAEs and of AEs leading to study withdrawal.
| Arm | Type | Description |
|---|---|---|
| 300 mg | ACTIVE_COMPARATOR | High Dose CT1812 |
| 100 mg | ACTIVE_COMPARATOR | Low Dose CT1812 |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo |
| Name | Type | Description |
|---|---|---|
| Active Treatment- CT1812 100 mg | DRUG | CT1812 |
| Active Treatment- CT1812 300 mg | DRUG | CT1812 |
| Placebo | DRUG | Matching Placebo |
Inclusion Criteria: * Participants may be included in the study only if they meet all of the following criteria: 1. Men, and women of non-childbearing potential, 50-85 years of age inclusively, with a diagnosis of mild to moderate Alzheimer's disease according to the 2011 NIA-AA criteria and at ...
Top 20 of 30 competitors
Active Treatment- CT1812 is an investigational small molecule being developed by Cognition Therapeutics, Inc. for Alzheimer disease. It is a Phase 1 clinical-stage candidate that has been studied in a completed trial evaluating its effect on brain synaptic density. It is not an approved therapy.
Active Treatment- CT1812 is being studied for use in Alzheimer disease. The completed Phase 1 trial NCT03493282 evaluated the effect of CT1812 treatment on brain synaptic density in participants with Alzheimer disease. It remains investigational and is not approved for any indication.
Active Treatment- CT1812 is being developed by Cognition Therapeutics, Inc., which trades under the ticker CGTX. The company is the sponsor of the clinical program for this small molecule candidate in Alzheimer disease.
Active Treatment- CT1812 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The program remains investigational and has not been approved by the FDA for any use.
Active Treatment- CT1812 has been studied in one completed Phase 1 trial, NCT03493282, titled Effect of CT1812 Treatment on Brain Synaptic Density. The trial enrolled 43 participants with Alzheimer disease in the United States and was randomized, double-blind, and placebo-controlled.